---
input_text: 'Pulmonary function in children and adolescents with sickle cell disease
  after nonmyeloablative hematopoietic cell transplantation.BACKGROUND: Pulmonary
  complications are common in sickle cell disease (SCD). The use of standard myeloablative
  conditioning regimens may increase the risk of lung injury. We report serial pulmonary
  function testing (PFT) outcomes in children with SCD who underwent a matched-sibling
  donor hematopoietic cell transplantation (HCT) using nonmyeloablative (NMA) protocol.
  METHODS: This is a retrospective chart review describing pulmonary outcomes in pediatric
  patients post HCT. The conditioning regimen consisted of alemtuzumab and a single
  fraction of 300 cGy of total body irradiation (TBI), and sirolimus for graft-versus-host
  disease (GVHD) prophylaxis. Serial PFT testing was performed pre and post HCT. The
  evaluated pulmonary measures included: forced vital capacity (FVC), forced expiratory
  volume in the first second (FEV1 ), FEV1 /FVC, and forced expiratory flow (FEF25-75
  ). RESULTS: Twelve subjects were included in the analysis. All had HbSS genotype,
  and five of the 12 patients had one or more episodes of acute chest syndrome prior
  to HCT. Serial PFT measures were completed per patient. No patient was diagnosed
  with chronic GVHD of any organ post HCT. The baseline median FVC, FEV1 , FEV1 /FVC,
  and FEF25-75 were within the normal range and remained relatively unchanged post
  HCT. A linear mixed effects model, adjusting for gender and time from HCT, suggested
  no significant relationship between HCT and PFT parameters, including FVC, FEV1
  , and FEV1 /FVC. Interestingly, the FEF25-75 results exhibited a shift in the means
  post HCT (pre-HCT 86.2% predicted and post-HCT 93.05% predicted, p-value = .018).
  CONCLUSION: Our study suggests that HCT in children with SCD may prevent the anticipated
  decline in pulmonary function over time.'
raw_completion_output: |-
  primary_disease: Sickle cell disease

  medical_actions: nonmyeloablative hematopoietic cell transplantation (HCT); serial pulmonary function testing (PFT); use of alemtuzumab; total body irradiation (TBI); sirolimus for GVHD prophylaxis

  symptoms: acute chest syndrome; decline in pulmonary function

  chemicals: alemtuzumab; sirolimus

  action_annotation_relationships: nonmyeloablative hematopoietic cell transplantation (HCT) PREVENTS decline in pulmonary function IN Sickle cell disease; use of alemtuzumab TREATS symptom IN Sickle cell disease; sirolimus for GVHD prophylaxis TREATS symptom IN Sickle cell disease
prompt: |+
  From the text below, extract the following entities in the following format:

  subject_extension: <A chemical or drug mentioned in the relationship between the medical action and the symptom, for example, "analgesic agent therapy" has the aspect "analgesic">
  object_extension: <An optional term describing some specific aspect of the object, e.g. "analgesic agent therapy" has the aspect "analgesic">
  subject: <The medical action. For example: blood transfusion, radiation therapy, cardiac catheterization, pulse oximetry, otoscopy>
  predicate: <The relationship type between the medical action and the symptom, usually TREATS or PREVENTS.>
  object: <A sign or symptom associated with the disease and targeted by the medical action. For example, Low serum calcitriol, hypoplasia of the thymus, chronic cough, aortic stiffness, low pulse pressure>
  qualifier: <The primary disease the relationship is about, or specifically the disease the symptom is related to. For example, Beck-Fahrner syndrome, hereditary retinoblastoma, progeria, diabetes mellitus, infectious otitis media>
  subject_qualifier: <An optional qualifier or modifier for the subject of the statement, e.g. "high dose" or "intravenously administered">
  object_qualifier: <An optional qualifier or modifier for the object of the statement, e.g. "severe" or "with additional complications">


  Text:
  sirolimus for GVHD prophylaxis TREATS symptom IN Sickle cell disease

  ===

extracted_object:
  primary_disease: MONDO:0011382
  medical_actions:
    - MAXO:0000149
    - serial pulmonary function testing (PFT)
    - use of alemtuzumab
    - total body irradiation (TBI)
    - sirolimus for GVHD prophylaxis
  symptoms:
    - acute chest syndrome
    - decline in pulmonary function
  chemicals:
    - alemtuzumab
    - CHEBI:9168
  action_annotation_relationships:
    - subject: MAXO:0000149
      predicate: PREVENTS
      object: decline in pulmonary function
      qualifier: MONDO:0011382
      subject_qualifier: nonmyeloablative
      subject_extension: hematopoietic cell transplantation
    - subject: use of alemtuzumab
      predicate: TREATS
      object: symptom
      qualifier: MONDO:0011382
      subject_extension: alemtuzumab
    - subject: GVHD prophylaxis
      predicate: TREATS
      object: symptom
      qualifier: MONDO:0011382
      subject_qualifier: for
      subject_extension: CHEBI:9168
named_entities:
  - id: MONDO:0011382
    label: Sickle Cell Anemia
  - id: MONDO:0007374
    label: Sickle cell disease (SCD)
  - id: MAXO:0000747
    label: Allogeneic hematopoietic stem cell transplantation (HSCT)
  - id: MAXO:0000756
    label: blood transfusion
  - id: CHEBI:33281
    label: antibiotics
  - id: HP:0001944
    label: dehydration
  - id: HP:0007760
    label: Sickle Cell Disease (SCD) symptoms
  - id: HP:0012592
    label: Albuminuria
  - id: HP:0012622
    label: Chronic kidney disease
  - id: HP:0100543
    label: cognitive deficits
  - id: MAXO:0001001
    label: Gene therapy
  - id: HP:0002863
    label: myelodysplastic syndrome
  - id: HP:0004808
    label: acute myeloid leukemia
  - id: CHEBI:28901
    label: busulfan
  - id: HP:0010972
    label: Ineffective erythropoiesis
  - id: HP:0001878
    label: Hemolytic anemia
  - id: HP:0001903
    label: Anemia
  - id: CHEBI:35143
    label: Hemoglobin (HbS)
  - id: CHEBI:44423
    label: hydroxycarbamide
  - id: MONDO:0020380
    label: Sickle cell anemia (SCA)
  - id: MONDO:0002120
    label: Nasopharyngeal neuroendocrine carcinoma (NEC)
  - id: HP:0030828
    label: wheeze
  - id: HP:0012735
    label: cough
  - id: MONDO:0003664
    label: Haemolytic anaemias
  - id: HP:0032654
    label: Endothelial dysfunction
  - id: HP:0025464
    label: Oxidative stress
  - id: CHEBI:17627
    label: Haem
  - id: CHEBI:18248
    label: Iron
  - id: CHEBI:197439
    label: TNFalpha
  - id: MAXO:0000149
    label: haploidentical hematopoietic cell transplant (HCT)
  - id: MONDO:0005570
    label: Blood disorders
  - id: HP:0002617
    label: Vasculopathy
  - id: HP:0010885
    label: Bone infarctions
  - id: MONDO:0013517
    label: beta-thalassemia
  - id: HP:0001945
    label: fever
  - id: HP:0033050
    label: sore throat
  - id: HP:0002315
    label: headache
  - id: HP:0001394
    label: Cirrhosis
  - id: HP:0002204
    label: Pulmonary embolus
  - id: HP:0001297
    label: Stroke
  - id: HP:0031033
    label: Renal acidification defect
  - id: HP:0032632
    label: Renal papillary necrosis
  - id: HP:0000093
    label: Proteinuria
  - id: HP:0003774
    label: End-stage renal disease
  - id: HP:0012213
    label: Decreased glomerular filtration rate (GFR)
  - id: CHEBI:59163
    label: biomarkers
  - id: MAXO:0000915
    label: Standardized polysomnography (PSG)
  - id: HP:0002360
    label: Sleep disturbances
  - id: HP:0034312
    label: Nocturnal hypoxemia
  - id: CHEBI:35482
    label: opioid analgesics
  - id: MONDO:0005148
    label: type II diabetes
  - id: MAXO:0000058
    label: Pharmacotherapy
  - id: MAXO:0000457
    label: Pain management
  - id: CHEBI:18050
    label: L-glutamine
  - id: HP:0004421
    label: Elevated systolic blood pressure
  - id: HP:0030515
    label: Moderate visual impairment
  - id: HP:0000618
    label: Blindness
  - id: CHEBI:68579
    label: rivaroxaban
  - id: CHEBI:24261
    label: glucocorticoids
  - id: HP:0012532
    label: Chronic pain
  - id: CHEBI:6121
    label: Ketamine
  - id: MONDO:0010631
    label: Acute ischemic priapism (IP)
  - id: CHEBI:8093
    label: Phenylephrine
  - id: CHEBI:35480
    label: Analgesics
  - id: CHEBI:35705
    label: immunosuppressive agents
  - id: MAXO:0000503
    label: Mechanical ventilation
  - id: CHEBI:25555
    label: Nitrogen
  - id: HP:0001396
    label: Cholestasis
  - id: HP:0000083
    label: Kidney failure
  - id: CHEBI:50858
    label: Corticosteroids
  - id: CHEBI:9570
    label: thiotepa
  - id: CHEBI:4027
    label: cyclophosphamide
  - id: MAXO:0000494
    label: Blood pressure monitoring
  - id: HP:0003006
    label: lack of universal newborn screening (NBS)
  - id: MONDO:0002049
    label: Thrombocytopenia
  - id: MAXO:0001017
    label: vaccination
  - id: HP:0001873
    label: Thrombocytopenia
  - id: MONDO:0100096
    label: COVID-19
  - id: CHEBI:46195
    label: Acetaminophen
  - id: CHEBI:47381
    label: Diclofenac
  - id: MAXO:0000861
    label: Labor induction
  - id: HP:0100602
    label: Preeclampsia
  - id: CHEBI:16199
    label: Urea
  - id: CHEBI:16737
    label: Creatinine
  - id: MAXO:0000748
    label: Fecal microbiota transplantation (FMT)
  - id: CHEBI:17968
    label: Butyrate
  - id: CHEBI:31011
    label: Valerate
  - id: CHEBI:17272
    label: Propionate
  - id: MONDO:0020121
    label: muscular dystrophy
  - id: HP:0002664
    label: cancer
  - id: HP:0000819
    label: diabetes
  - id: MONDO:0004992
    label: cancer
  - id: MONDO:0005015
    label: diabetes
  - id: MAXO:0000610
    label: Enzyme-linked immunosorbent assay
  - id: HP:0007018
    label: Attention deficits
  - id: HP:0000848
    label: Increased plasma renin
  - id: CHEBI:48432
    label: Angiotensin II
  - id: CHEBI:4784
    label: Enalapril
  - id: HP:0100749
    label: Chest pain
  - id: HP:0002094
    label: Shortness of breath
  - id: HP:0000716
    label: Depression
  - id: HP:0001627
    label: Cardiac abnormalities
  - id: MONDO:0042491
    label: Contrast-induced nephropathy (CIN)
  - id: HP:0003259
    label: Elevated serum creatinine (SCr)
  - id: MONDO:0005399
    label: Venous thromboembolism (VTE)
  - id: MONDO:0054550
    label: Avascular Necrosis of the Femoral Head (AVNFH)
  - id: MAXO:0000004
    label: surgical intervention
  - id: HP:0012531
    label: pain
  - id: HP:0000969
    label: oedema
  - id: HP:0002140
    label: Ischemic cerebrovascular accidents
  - id: HP:0002098
    label: respiratory distress
  - id: HP:0002092
    label: Pulmonary hypertension
  - id: CHEBI:27690
    label: Acetazolamide (ACZ)
  - id: CHEBI:48021
    label: Peptide nucleic acid (PNA)
  - id: CHEBI:53374
    label: Poly Lactic-co-Glycolic Acid (PLGA)
  - id: MONDO:0006079
    label: Acute chest syndrome (ACS)
  - id: MONDO:0005632
    label: Acute chest syndrome
  - id: CHEBI:6443
    label: Levonorgestrel
  - id: HP:0001518
    label: Small for gestational age
  - id: HP:0001622
    label: Preterm
  - id: CHEBI:8735
    label: PAINReportIt(R)
  - id: MAXO:0000376
    label: liver biopsy
  - id: MAXO:0000066
    label: Oxygen supplementation
  - id: MAXO:0001175
    label: Liver transplantation
  - id: HP:0001395
    label: Liver fibrosis
  - id: MONDO:0044348
    label: Hemoglobinopathies
  - id: CHEBI:9168
    label: sirolimus
